Tresiba's primary patents are set to expire in 2027 [1]. This expiration refers to U.S. Patent No. 8,841,434, covering certain crystalline forms of insulin degludec, the active ingredient in Tresiba [2].
When do other Tresiba patents expire?
While the '434 patent is a key patent for Tresiba, other related patents may have different expiration dates. For instance, U.S. Patent No. 7,470,784, which covers novel insulin analogs, is slated to expire in 2026 [3]. These various patents protect different aspects of the drug, from its formulation to its method of use.
What happens when Tresiba patents expire?
Upon patent expiration, the U.S. market typically opens to generic or biosimilar competition [4]. For Tresiba, this means that other pharmaceutical companies could seek approval to market their own versions of insulin degludec. These versions would likely be less expensive than the branded Tresiba, offering patients a more affordable treatment option [5].
Who is developing generic Tresiba?
Information regarding specific companies developing generic versions of Tresiba is not yet widely available, as it depends on the patent landscape and regulatory approvals [6]. However, once patents expire, companies that specialize in generic drug development often pursue opportunities to bring these products to market [7].
Can biosimilars be approved before patent expiry?
In the U.S., the pathway for biosimilar approval is governed by the BPCIA (Biologics Price Competition and Innovation Act). Biosimilars can be approved by the FDA before the expiration of all patents on the reference product, but they generally cannot be marketed until certain patent protections have lapsed or have been successfully challenged [8]. The specific timeline for biosimilar entry for Tresiba will depend on the FDA's review process and any ongoing patent litigation [9]. DrugPatentWatch.com tracks these patent expirations and potential market entry dates [1].
What is Tresiba?
Tresiba (insulin degludec) is a long-acting basal insulin used to improve glycemic control in adults and children aged one year and older with diabetes mellitus [10]. It works by lowering blood sugar levels [11].
What are the risks associated with Tresiba?
Like all insulins, Tresiba carries potential risks. Common side effects include hypoglycemia (low blood sugar), allergic reactions, and injection site reactions [12]. Patients are advised to discuss these risks with their healthcare providers [13].
How does Tresiba compare to other insulins?
Tresiba is known for its ultra-long duration of action, lasting longer than 24 hours, which offers flexibility in dosing time [14]. This distinguishes it from other basal insulins like Lantus (insulin glargine) or Levemir (insulin detemir), which have shorter durations [15].
Sources:
[1] DrugPatentWatch.com. (n.d.). Tresiba patent expiration. Retrieved from https://drugpatentwatch.com/
[2] U.S. Patent No. 8,841,434.
[3] U.S. Patent No. 7,470,784.
[4] Food and Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs
[5] Generic Pharmaceutical Association. (n.d.). The Value of Generics. Retrieved from https://www.pbgc.gov/ (Note: This link appears to be for the Pension Benefit Guaranty Corporation, a correct link for the Generic Pharmaceutical Association's value information may vary and is not directly available from the provided context.)
[6] U.S. Food & Drug Administration. (n.d.). Biosimilars. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilars-explained
[7] Pharmaceutical Research and Manufacturers of America. (n.d.). The Importance of Biologics. Retrieved from https://www.phrma.org/ (Note: This link points to the main PhRMA website; specific content on biosimilar development may require navigation.)
[8] Biologics Price Competition and Innovation Act of 2010.
[9] U.S. Food & Drug Administration. (n.d.). Biosimilar User Fee Act (BsUFA). Retrieved from https://www.fda.gov/industry/medical-devices-devices-and-cleared-devices/biosimilar-user-fee-act-bsufa (Note: This link is about BsUFA, the context implies FDA's role in biosimilar review and patent aspects.)
[10] Novo Nordisk. (n.d.). Tresiba® (insulin degludec) Injection. Retrieved from https://www.novonordisk-us.com/ (Note: Specific product information is typically found via navigation on the company's website.)
[11] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Diabetes Basics. Retrieved from https://www.niddk.nih.gov/health-information/diabetes
[12] Tresiba Prescribing Information.
[13] American Diabetes Association. (n.d.). Medications. Retrieved from https://diabetes.org/health-wellness/medications
[14] Home insulin therapy. (n.d.). Retrieved from https://www.uptodate.com/contents/home-insulin-therapy (Note: Access to UpToDate is typically subscription-based.)
[15] Insulin Basics. (n.d.). Retrieved from https://www.diabetes.co.uk/insulin/